Arca biopharma announces submission of ind application to u.s. fda for ab201 as a potential treatment for covid-19

Arca biopharma announces submission of ind application to u.s. fda for ab201 as a potential treatment for covid-19.arca biopharma - pending fda feedback, anticipates initiating phase 2b portion of sequential phase 2b/3 clinical evaluation of ab201 as early as q4 of this year.
ABIO Ratings Summary
ABIO Quant Ranking